Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up

Table 2 Audiometry findings, present regimen and length of aminoglycoside use in all four patients using capreomycin (Group III)

Sr. No.	Length of treatment (Days)	Present regimen (Drugs)	PTA0	PTA2	PTA4	PTA6	PTA8	PTA10	PTAc
1	247	C, F, E, P, Clo	N	N	N	N	N	N	N
2	254	C, F, E, P, Clo	N	N	N	N	N	N	N
3*	120	C, F, E, P, Clo	N	N	HFL	HFL	HFL	HFL	HFL
4	240	C, F, E, P, Clo	N	N	N	N	N	N	N

C = capreomycin, F = flouroquinolone, E = ethionamide, P = Paraminosalicylic acid, Clo = Clofazimine, Days = days of aminoglycoside use in present regimen, PTA0 = baseline pure tone audiogram, PTA2 = pure tone audiogram after 2 months of aminoglycoside use, PTA4 = pure tone audiogram after 4 months of aminoglycoside use, PTA6 = pure tone audiogram after 6 months of aminoglycoside use, PTA8 = pure tone audiogram after 8 months of aminoglycoside use, PTA10 = pure tone audiogram after 10 months of aminoglycoside use, PTAc = pure tone audiogram after completion of therapy for MDR-TB, N = Normal, HFL = High frequency loss (hearing loss involving frequencies of 4000, 6000 and 8000 Hz), FLAT = Hearing loss involving frequencies in range of 250–3000 Hz along with involvement of 4000, 6000 and 8000 Hz (Criteria for hearing loss as defined in methods section). * Patient in group III with audiological evidence of hearing loss

ISSN: 1472-6815